U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07429474) titled 'Safety and Immunogenicity of PRO-169 in Patients With Diabetic Macular Edema' on Feb. 17.
Brief Summary: Phase I, prospective, interventional, open-label, multicenter clinical trial to evaluate the safety of intravitreal PRO-169 through the presence of serum anti-drug antibodies (ADAs) to bevacizumab.
Study Start Date: March 01
Study Type: INTERVENTIONAL
Condition:
Immunogenicity
Anti-drug Antibodies (ADAs)
Intervention:
BIOLOGICAL: PRO-169
Bevacizumab 1.25 mg / 0.05mL for intravitreal injection.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Laboratorios Sophia S.A de C.V.
Published by HT Digital Content Services with pe...